{
    "root": "2af91a53-9d36-4415-b4f3-cd78b8ad36ad",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Methoxsalen"
    },
    "value": "20250311",
    "ingredients": [
        {
            "name": "METHOXSALEN",
            "code": "U4VJ29L7BQ"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "GLYCINE",
            "code": "TE7660XO1C"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "MEDIUM-CHAIN TRIGLYCERIDES",
            "code": "C9H2L21V7U"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "photochemotherapy ( methoxsalen long wave uva radiation ) indicated symptomatic control severe , recalcitrant , disabling psoriasis adequately responsive forms therapy diagnosis supported biopsy . methoxsalen intended administered conjunction schedule controlled doses long wave ultraviolet radiation .",
    "contraindications": "caution : methoxsalen capsules , usp represents new dose form methoxsalen . new form methoxsalen exhibits significantly greater bioavailability earlier photosensitization onset time previous methoxsalen forms . patient evaluated determining minimum phototoxic dose ( mpd ) phototoxic peak time prior onset photochemotherapy form . human bioavailability indicated following directions used guideline .",
    "warningsAndPrecautions": "methoxsalen capsules , usp 10 mg green color , oval shaped soft gelatin capsule imprinted 'm10 ' containing crystals clear colorless pale yellow liquid , containing 10 mg methoxsalen ( 8-methoxypsoralen ) . packed amber colored glass bottles 50 's count ( ndc 64380-752-16 ) . store 20\u00b0 25 \u00b0c ( 68\u00b0 77 \u00b0f ) ; excursions permitted 15 \u00b0c - 30 \u00b0c ( 59 \u00b0f - 86 \u00b0f ) . [ usp controlled room temperature ] manufactured : strides pharma science ltd. bengaluru - 562106 , india distributed : strides pharma inc. east brunswick , nj 08816",
    "adverseReactions": "a. patients exhibiting idiosyncratic psoralen compounds . b. patients possessing history light sensitive disease states initiate methoxsalen therapy except special circumstances . diseases associated photosensitivity include lupus erythematosus , porphyria cutanea tarda , erythropoietic protoporphyria , variegate porphyria , xeroderma pigmentosum , albinism . c. patients melanoma history melanoma . d. patients invasive squamous cell carcinomas . e. patients aphakia , significantly increased risk retinal damage due absence lenses .",
    "indications_original": "Photochemotherapy (Methoxsalen with long wave UVA radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy. Methoxsalen is intended to be administered only in conjunction with a schedule of controlled doses of long wave ultraviolet radiation.",
    "contraindications_original": "CAUTION: Methoxsalen Capsules, USP represents a new dose form of methoxsalen. This new dosage form of methoxsalen exhibits significantly greater bioavailability and earlier photosensitization onset time than previous methoxsalen dosage forms. Each patient should be evaluated by determining the minimum phototoxic dose (MPD) and phototoxic peak time after drug administration prior to onset of photochemotherapy with this dosage form. Human bioavailability studies have indicated the following drug dosage and administration directions are to be used as a guideline only.",
    "warningsAndPrecautions_original": "Methoxsalen Capsules, USP 10 mg is green color, oval shaped soft gelatin capsule imprinted with 'M10' containing no drug crystals and clear colorless to pale yellow liquid, each containing 10 mg of methoxsalen (8-methoxypsoralen).\u00a0 It is packed in amber colored glass bottles as 50's count (NDC 64380-752-16). \n                  Store at 20\u00b0 to 25 \u00b0C (68\u00b0 to 77 \u00b0F); excursions permitted between 15 \u00b0C - 30 \u00b0C (59 \u00b0F - 86 \u00b0F). \n                  [See USP Controlled Room Temperature]\n                  \n                     Manufactured by:\n                  \n                  Strides Pharma Science Ltd.\n                  Bengaluru - 562106, India\n                  \n                     Distributed by:\n                  \n                  Strides Pharma Inc.\n                  East Brunswick, NJ 08816",
    "adverseReactions_original": "A.\u00a0\u00a0\u00a0 Patients exhibiting idiosyncratic reactions to psoralen compounds.\n                  B.\u00a0\u00a0\u00a0\u00a0 Patients possessing a specific history of light sensitive disease states should not initiate methoxsalen therapy except under special circumstances. Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.\n                  C.\u00a0\u00a0\u00a0\u00a0 Patients with melanoma or with a history of melanoma.\n                  D.\u00a0\u00a0\u00a0 Patients with invasive squamous cell carcinomas.\n                  E.\u00a0\u00a0\u00a0\u00a0 Patients with aphakia, because of the significantly increased risk of retinal damage due to the absence of lenses."
}